Clinical trials: Sjogren's Syndrome
Sjogren's Syndrome
B-dependant Rare AutoImmune diseaSES - Cohort of Patients With Suspected Diagnosis of Primitive Sjögren Syndrome
The objectif is to study the diagnosis performance of the different classification criteria in reference to the gold standard consisting of the diagnosis made by expert doctors after standardized assessment, of pSS (primary…
- Trial name
- BRAISES-DiaPSS (NCT04931160)
- Testing
- Blood, fluid, sells and urine samples
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Brest
Sjogren's Syndrome
Comprehensive Evaluation of Clinical and Biopsychosocial Characteristics in Primary Sjögren's Disease
Following the guidance of individuals with primary Sjögren's Syndrome who receive diagnosis, routine medical care, and treatment management, the evaluations will be performed once by the researchers and will take approximately…
- Trial name
- NCT06410742
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kahramanmaras Sutcu Imam University
Autoimmune Diseases, Sjogren's Syndrome
Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome
Primary Sjögren syndrome is one of the most prevalent autoimmune diseases that present with dry eye and dry mouth. But there is no proven effective treatment for Sjögren syndrome patient.
- Conditions
- Autoimmune Diseases, Sjogren's Syndrome, Dry Eye
- Trial name
- NCT01601028
- Testing
- Hydroxychloroquine
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Seoul National University Hospital
Sjogren's Syndrome, Dry Eye
AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye
The objective of the present study was to evaluate the efficacy of autologous serum tears combined with 0.05% cyclosporin eye drop in treating Sjögren's syndrome dry eye and their effect on corneal nerves.
- Conditions
- Sjogren's Syndrome, Dry Eye, Ocular Surface Disease
- Trial name
- AST/SS (NCT06013436)
- Testing
- Autologous serum tears combined with 0.05% cyclosporin eye drop
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Diet Habit, Rheumatologic Disease
Rheumatology Diet Study
This study aims to collect information on rheumatology patients' dietary habits, autoimmune disease activity, dietary changes, disease symptom improvements, and perceptions on their dietary habits and how it affects their…
- Conditions
- Diet Habit, Rheumatologic Disease, Autoimmune Diseases, Rheumatoid Arthritis
- Trial name
- NCT06339957
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Central Florida
Rheumatoid Arthritis, Systemic Lupus
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
The overall objective of this project is to study the influence of modern anti-inflammatory treatments in established inflammatory rheumatic diseases (IRD) on antibody response elicited by pneumococcal vaccination using 13-valent…
- Conditions
- Rheumatoid Arthritis, Systemic Lupus, Sjögren Syndrome, Systemic Vasculitis
- Trial name
- IPS-BOOSTER (NCT03762824)
- Testing
- 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Region Skane
Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Autoimmune diseases refer to a common category of diseases caused by the immune system reacting to self-antigens, leading to tissue damage.
- Conditions
- Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Sjogren Syndrome, ANCA Associated Vasculitis (AAV)
- Trial name
- NCT06828042
- Testing
- anti-CD19 CAR T cell therapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Peking University Third Hospital
Sjogren's Syndrome, Pediatric ALL
Belimumab After Rituximab in Resistant Primary Juvenile SS
The goal of this clinical trial is to explore the effectiveness of sequential use of rituximab and belimumab in the treatment of resistant primary juvenile Sjogren's syndrome.
- Trial name
- BRRPJS (NCT06410833)
- Testing
- Rituximab, Belimumab
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking Union Medical College Hospital
Primary Sjögren Syndrome
A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.
The purpose of this study is to evaluate the efficacy and safety of iguratimod compared to placebo in patients with active primary Sjogren's Syndrome.
- Trial name
- NCT04830644
- Testing
- Iguratimod
- Where
- 30 sites in China
- Volunteers
- 144 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Congenital Heart Block, Neonatal Lupus
Preventive IVIG Therapy for Congenital Heart Block
Neonatal lupus (NL) is the name given to a group of conditions that can affect the babies of mothers who have certain autoantibodies against components of the body's cells that are called SSA/Ro and SSB/La.
- Conditions
- Congenital Heart Block, Neonatal Lupus, Autoantibody-associated Heart Block
- Trial name
- PITCH (NCT00460928)
- Testing
- intravenous immune globulin (IVIG)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Sjogren Syndrome
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)
- Trial name
- NEPTUNUS-2 (NCT05349214)
- Testing
- VAY736
- Where
- 146 sites in United States, Argentina and 24 more
- Volunteers
- 506 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erthematosus, Sjogren's Syndrome
Omalizumab for Lupus
Background: Systemic Lupus Erythematosus (SLE or lupus) is an autoimmune disease, which means the body's immune system mistakenly attacks healthy tissue resulting in inflammation and tissue damage.
- Trial name
- NCT01716312
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Dry Eye Syndrome, Epiphora
Optical Coherence Tomography of Ocular Structures in Epiphora and Dry Eye Syndrome.
The primary aim of the study is to investigate whether optical coherence tomography (OCT) may be a useful tool for investigating the in-vivo histology of ocular structures in patients with tear film pathology.
- Conditions
- Dry Eye Syndrome, Epiphora, Sjögren's Syndrome
- Trial name
- OCT (NCT02849093)
- Testing
- Non-invasive OCT imaging
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bedford Hospital NHS Trust
Inflammation, Sjogren's Syndrome
Superb Microvascular Imaging Ultrasonography of Lacrimal Gland in Patients With Sjögren Syndrome
A prospective study will be conducted to evaluate inflammatory activity in lacrimal glands due to Sjögren's syndrome on Superb Microvascular Imaging (SMI), gray scale ultrasound (US), color Doppler US and Power Doppler US.
- Conditions
- Inflammation, Sjogren's Syndrome, Gland; Inflammation
- Trial name
- SMI (NCT05689749)
- Testing
- Superb Microvascular Imaging (SMI) (Toshiba)
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Nigde Omer Halisdemir University
Systemic Lupus Erythematosus, Inflammatory Myopathy
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis
- Trial name
- NCT06794008
- Testing
- BCMA-CD19 CAR-T therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Sjogren's Syndrome
Ultra-High Frequency Ultrasonography in Sjögren's Syndrome
Patients diagnosed with a diagnosis of Sjogren's syndrome performed according to the ACR/EULAR criteria will be included in the study.
- Trial name
- UltraSjögren (NCT06338735)
- Testing
- Ultra-High Frequency Ultrasound scan of minor salivary glands
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- University of Pisa
Sjogren's Syndrome (SS)
An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)
Sjogren's syndrome (SS) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement.
- Trial name
- NCT05217472
- Testing
- Ravaglimab, Ravagalimab
- Where
- Netherlands
- Sponsor
- AbbVie
Sjogren's Syndrome, Autoimmune Diseases
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome
- Trial name
- NCT05085431
- Testing
- Assigned Interventions CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Zhejiang University
Sjogren's Syndrome
Acupuncture for Primary Sjögren Syndrome
The purpose of this study is to determine whether acupuncture is effective and safe in the treatment of Primary Sjögren Syndrome.
- Trial name
- NCT02691377
- Testing
- acupuncture group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Sjögren's Disease
A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).
- Trial name
- NCT07836660
- Testing
- Part B -Telitacicept, Part A - IBI355
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.